Table 2 Baseline demographics and clinical characteristics for the influenza vaccination population
Characteristic | Influenza vaccine population (N = 191) |
|---|---|
Age | |
 Mean (SD), years | 44.9 (12.6) |
Sex | |
 Women, n (%) | 172 (90.1) |
 Men, n (%) | 19 (9.9) |
Race | |
 White, n (%) | 188 (98.4) |
 Black/African American, n (%) | 2 (1.0) |
 Other, n (%) | 1 (0.5) |
Region | |
 South America, n (%) | 156 (81.7) |
 North America, n (%) | 35 (18.3) |
Weight | |
 Mean (SD), kg | 68.4 (17.3) |
Duration of abatacept exposure during main study | |
 Mean (SD), months | 37.6 (2.9) |
Tender joint count/28 | |
 Mean (SD) | 30.7 (14.4) |
Swollen joint count/28 | |
 Mean (SD) | 20.3 (8.0) |
Patient pain | |
 100-mm VAS, mean (SD) | 65.5 (22.2) |
HAQ-DI | |
 Mean (SD) | 1.7 (0.6) |
C-reactive protein, | |
 Mean (SD), mg/dL | 2.4 (2.7) |
Patient global assessment | |
 100-mm VAS, mean (SD) | 64.7 (21.5) |
Physician global assessment, 100-mm VAS | |
 100-mm VAS, mean (SD) | 60.3 (17.9) |
DAS28 (C-reactive protein) | |
 Mean (SD) | 6.3 (0.8) |
Concomitant methotrexate | |
  n (%) | 186 (97.4) |